Liquid chromatographic determination of urinary 5-methyl-2'-deoxycytidine and pseudouridine as potential biological markers for leukaemia

J Pharm Biomed Anal. 1999 Dec;21(5):1045-51. doi: 10.1016/s0731-7085(99)00221-6.

Abstract

A simple reversed-phase liquid chromatographic (LC) method for the determination of urinary 5-methyl-2'-deoxycytidine (m5dCyd), recently claimed (on the basis of an imuno-technique) to be a potential marker for leukaemia, has been developed. Sample pre-treatment is based on a microcolumn clean-up step with an average recovery of 79% and a RSD of 3%. Detection limit was 0.2 microg/ml which is about tenfold lower than levels previously measured by an ELISA method in urine of healthy individuals. The creatinine (Cre) excretion, necessary for normalising the m5dCyd excretion, was evaluated by ion-pair liquid chromatography which permitted the simultaneous determination of pseudouridine (psi), a modified nucleoside also potentially useful as a marker for leukaemia. The described LC procedures were applied to the analysis of urine samples from healthy individuals and leukaemia patients. While the urinary psi/Cre ratio was found significantly increased for leukaemia patients, the urinary m5dCyd levels in healthy individuals were below the detection limits and did not increase in presence of the malignant disease.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Biomarkers, Tumor / urine
  • Chromatography, High Pressure Liquid
  • Deoxycytidine / analogs & derivatives*
  • Deoxycytidine / urine
  • Female
  • Humans
  • Leukemia / urine*
  • Leukemia, Myeloid / urine
  • Male
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / urine
  • Pseudouridine / urine*
  • Sensitivity and Specificity

Substances

  • Biomarkers, Tumor
  • Deoxycytidine
  • Pseudouridine
  • 5-methyldeoxycytidine